(Q78035754)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

R Linder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

M Blombäck

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

N Egberg

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

L Grip

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 July 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

117-125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10418800%20AND%20SRC:MED&resulttype=core&format=json

Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Deficiency of protein C in congenital thrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Treatment of patients with disseminated intravascular coagulation by protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46???6240), recombinant hirudin and heparin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

Characterization of a protein C activator from the venom of Agkistrodon contortrix contortrix

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021

The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2899%2900029-8

7 January 2021